The Effects of Simvastatin on Experimental Schizophrenia Models in Mice

Creative Commons License

Yıldırım E., Kaygısız B.

ERCIYES MEDICAL JOURNAL, cilt.40, ss.23-27, 2018 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 40
  • Basım Tarihi: 2018
  • Doi Numarası: 10.5152/etd.2018.17091
  • Dergi Adı: ERCIYES MEDICAL JOURNAL
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.23-27
  • Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Objective: Statins, or 3-hydroxyl-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, which are potent inhibitors of cholesterol synthesis, are widely used in the treatment of hypercholesterolaemia and prevention of coronary artery diseases. Evidence from clinical trials also show other beneficial actions of statins unrelated to their cholesterol lowering effects. In experimental animal studies, it was reported that simvastatin, a statin agent, may alter dopaminergic and glutamatergic functions. Dopaminergic overactivity and dysfunction of glutamatergic transmission is associated with the pathogenesis of schizophrenia. This study aims to examine the chronical effects of simvastatin on experimental psychosis models in mice.